R Díez Valle1, J Slof2, J Galván3, C Arza3, C Romariz3, C Vidal4. 1. Departamento de Neurocirugía, Clínica Universidad de Navarra, Pamplona, España. Electronic address: rdiezvalle@unav.es. 2. Universidad Autónoma de Barcelona, Bellaterra, España. 3. Laboratorios Gebro Pharma S.A., Barcelona, España. 4. Needs and Aims, Barcelona, España.
Abstract
OBJECTIVE: To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(®)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6). MATERIAL AND METHODS: Retrospective review of data from 18 neurosurgery departments that were categorised as either using or not using 5-ALA. The study included adult patients with suspected malignant gliomas for whom the intended treatment plan included complete resection followed by radiotherapy and chemotherapy with temozolomide. Postoperative MRI and clinical data representing at least 6 months were required for inclusion. Rates of CR and PFS6 were compared between patients with 5-ALA treatment and those without. RESULTS: The study included 251 evaluable cases. CR and PFS6 rates were significantly higher in the group of patients treated surgically with 5-ALA: CR, 67% versus 45%, p=.000; PFS6 for patients with grade IV tumours, 69% versus 48%; p=.002. The differences retained their significance and magnitude after adjusting for all covariates including age, functional status, and whether gliomas were located in eloquent areas. CONCLUSIONS: In this retrospective series, use of 5-ALA during habitual surgical procedures in Spain was associated with a higher complete resection rate for malignant glioma and increased PFS6 for grade iv glioma.
OBJECTIVE: To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(®)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6). MATERIAL AND METHODS: Retrospective review of data from 18 neurosurgery departments that were categorised as either using or not using 5-ALA. The study included adult patients with suspected malignant gliomas for whom the intended treatment plan included complete resection followed by radiotherapy and chemotherapy with temozolomide. Postoperative MRI and clinical data representing at least 6 months were required for inclusion. Rates of CR and PFS6 were compared between patients with 5-ALA treatment and those without. RESULTS: The study included 251 evaluable cases. CR and PFS6 rates were significantly higher in the group of patients treated surgically with 5-ALA: CR, 67% versus 45%, p=.000; PFS6 for patients with grade IV tumours, 69% versus 48%; p=.002. The differences retained their significance and magnitude after adjusting for all covariates including age, functional status, and whether gliomas were located in eloquent areas. CONCLUSIONS: In this retrospective series, use of 5-ALA during habitual surgical procedures in Spain was associated with a higher complete resection rate for malignant glioma and increased PFS6 for grade iv glioma.
Authors: Tiffany A Eatz; Daniel G Eichberg; Victor M Lu; Long Di; Ricardo J Komotar; Michael E Ivan Journal: J Neurooncol Date: 2022-01-06 Impact factor: 4.130
Authors: Marcel A Kamp; Zarela Krause Molle; Christopher Munoz-Bendix; Marion Rapp; Michael Sabel; Hans-Jakob Steiger; Jan F Cornelius Journal: Neurosurg Rev Date: 2016-05-25 Impact factor: 3.042
Authors: Asfand Baig Mirza; Ioannis Christodoulides; Jose Pedro Lavrador; Anastasios Giamouriadis; Amisha Vastani; Timothy Boardman; Razna Ahmed; Irena Norman; Christopher Murphy; Sharmila Devi; Francesco Vergani; Richard Gullan; Ranjeev Bhangoo; Keyoumars Ashkan Journal: Neurooncol Adv Date: 2021-03-26